Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Study sponsor: Sellas Life Sciences Group
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-11-30Actual
Enrollment · participants41Actual
Source updated2024-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.